Altimmune, Inc. (ALT) earnings
ALT earnings moved a median of 0.00% by the close. Quarterly and annual ALT reports and results, each read against the price at its own news timestamp. Back to the ALT overview →
23 measured ALT earnings events.
Where these ALT earnings landedvs 21 measured ALT earnings reactions
| Middle 50% of ALT earnings reactions | -2.99% to +3.68% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 ALT earnings events with a measured close landed between -2.99% and +3.68%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Altimmune Announces Second Quarter 2026 Financial Results and Business Update | Press release | +1.15% | -3.93% | |
| Form 10-Q Altimmune, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.36% | -2.37% | |
| Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 | Press release | +1.30% | -1.30% | |
| Altimmune Announces First Quarter 2026 Financial Results and Business Update | Press release | -3.17% | +0.67% | |
| Form 10-Q Altimmune, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.83% | -2.99% | |
| Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 | Press release | -0.16% | +6.54% | |
| Form 10-K Altimmune, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.26% | +0.00% | |
| Altimmune Announces Third Quarter 2025 Financial Results and Business Updates | Press release | +1.71% | +3.68% | |
| Form 10-Q Altimmune, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.77% | +4.32% | |
| Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 | Press release | -0.25% | +0.49% | |
| Altimmune Announces Second Quarter 2025 Financial Results and Business Update | Press release | -1.43% | — | |
| Form 10-Q Altimmune, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.43% | — | |
| Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 | Press release | +0.70% | +3.38% | |
| Altimmune Announces First Quarter 2025 Financial Results and Business Update | Press release | -7.71% | -5.57% | |
| Form 10-Q Altimmune, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.04% | -1.55% | |
| Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 | Press release | -1.86% | -6.16% | |
| Form 10-K Altimmune, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.29% | +7.26% | |
| Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update | Press release | +10.37% | +24.54% | |
| Form 10-Q Altimmune, Inc. For: Sep 30 | SEC filing · Form 10-Q | +5.23% | -2.36% | |
| Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 | Press release | -1.97% | +1.50% | |
| Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update | Press release | -0.69% | +9.14% | |
| Form 10-Q Altimmune, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.78% | -3.59% | |
| Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 | Press release | -1.65% | -4.40% |
Keep exploring
More ALT: analyst actions → · SEC filings → · ALT overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GENMARK DIAGNOSTICS (GNMK) | 1,451 | +0.06% | 51% |
| GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) | 1,448 | +0.01% | 51% |
| PerkinElmer, Inc. (PKI) | 1,409 | +0.11% | 56% |
| Zoetis Inc. Class A (ZTS) | 1,406 | +0.02% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.